

Now that we are happy with the methodology we will proceed to examine the results



FLAWED SYSTEMATIC REVIEW?




Res

l+a	Analysis 1.1. Comparison 1 Treadmill (with or without body weight support) versus other intervention, Outcome 1 Walking speed (m/s) at end of treatment					
sults	Walking endurance (m) at end of treatment.	134				
	Analysis 2.1. Comparison 2 Treadmill and body weight support versus other interventions, Outcome 1 Dependence on personal assistance to walk at end of treatment. Analysis 2.2. Comparison 2 Treadmill and body weight support versus other interventions, Outcome 2 Walking speed	136				
	(m/s) at end of treatment	137				
	Analysis 2.3. Comparison 2 Treadmill and body weight support versus other interventions, Outcome 3 Walking endurance	٠)				
	Dropouts for all included trials, Outcome 1 Dropouts)				
-	ensitivity analysis: by trial methodology (all trials involving treadmill training), Outcome 1	ś 1				
	subgroup analysis: treadmill (with or without body weight support) versus other, by duration					
	n walking only), Outcome 1 Walking speed (m/s) at end of treatment	, 2				
	subgroup analysis: treadmill (with or without body weight support) versus other, by duration	3				
	n walking only), Outcome 2 Walking endurance (m) at end of treatment	,				
*	subgroup analysis: treadmill (with or without body weight support) versus other, by intensity independent in walking only), Outcome 1 Walking speed (m/s) at end of treatment	1				
	subgroup analysis: treadmill (with or without body weight support) versus other, by intensity	5				
	independent in walking only), Outcome 2 Walking endurance (m) at end of treatment.	5				
Analysis 10.1. Comparison 10	Subgroup analysis: treadmill (with or without body weight support) versus other, by duration	. 5				
01 . 1	pendent in walking only), Outcome 1 Walking speed (m/s) at end of treatment	,				
	pendent in walking only), Outcome 2 Walking endurance (m) at end of treatment	, '				
or training period (much	ent of screening form, of the state of the s	147				
	at end of scheduled follow-up.	148				
	Analysis 5.1. Comparison 5 Adverse events for all included trials, Outcome 1 Adverse events during the treatment.	149				



Start with PICO




In a person with stroke, will training with BWSTT compared to conventional therapy improve walking ability?



Mr Lee wants to know if BWSTT therapy could make him walk faster and for further distance.






Line of no difference



Analysis 2.2. Comparison 2 Treadmill and body weight support versus other interventions, Outcome 2

Walking speed (m/s) at end of treatment.

Regardless of walking ability at start of treatment






Heterogeneity: Tau² = 0.01; Chi² = 29.09, df = 17 (P = 0.03); l² = 42%

Test for overall effect Z = 3.95 (P = 0.000078)

Analysis 2.2. Comparison 2 Treadmill and body weight support versus other interventions, Outcome 2 Walking speed (m/s) at end of treatment.








Analysis 2.3. Comparison 2 Treadmill and body weight support versus other interventions, Outcome 3

Walking endurance (m) at end of treatment.

Regardless of walking ability at start of treatment





Analysis 2.3. Comparison 2 Treadmill and body weight support versus other interventions, Outcome 3 Walking endurance (m) at end of treatment.

Dependent in walking

Heterogeneity: $Tau^2 = 0.0$; $Chi^2 = 2.47$, $df = 4$ (P = 0.65); $P = 0.0\%$									
	Subtotal (95% CI)	392		247		+	41.8 % -5	.09 [-23.41, 13.22]	
	Kosak 2000	22	22.86 (75.8)	34	30.57 (71.99)	-	9.4 %	-7.71 [-47.57, 32.15]	
	Hoyer 2012	30	137.51 (94.6)	30	115.28 (83.54)	+	8.5 %	2223 [-22.93, 67.39]	
	Franceschini 2009	52	160 (83.7)	50	170 (118.5)	-	9.4 %	-10.00 [-49.95, 29.95]	
	Duncan 2011	282	186.3 (134.75)	126	202.2 (144.3)	-	11.2 %	-15.90 [-45.60, 13.80]	
	— Da Cunha Filho 2002	6	86.83 (111.16)	7	56.86 (58.7)		3.3 %	29.97 [-69.04, 128.98]	
	I dependent in walking at sta	art of trea	atment						

Test for overall effect: Z = 0.54 (P = 0.59)








Analysis 2.3. Comparison 2 Treadmill and body weight support versus other interventions, Outcome 3 Walking endurance (m) at end of treatment.

Independent in walking

MacKay-Lyons 2013	24	278.6 (88.6)	26	232 (80.1)
Middleton 2014	27	337.98 (203.93)	23	239.46 (165.77)
Moore 2010	15	276 (130)	15	201 (134)
Srivastava 2016	10	285.38 (85.1)	10	290 (67.13)
Sullivan 2007	60	235.6 (125.5)	20	170.5 (122.8)

Subtotal (95% CI) 233 190 Heterogeneity: Tau² = 627.40; Chi² = 14.80, df = 9 (P = 0.10); I² = 39%

Test for overall effect 7 = 2.81 (P = 0.0050)





In the short term, patients who are walking independently at the start of treatment:

- Increase walking speed by 0.11m/s (0.06 0.17m/s) Increase walking endurance by 37m (11-63m)

No significant difference if dependent in walking at the start of treatment

Mr Lee walks independently





Long term?



In summary, BWSTT compared to conventional therapy:

In the short term, patients who are walking independently at the start of treatment:

- Increase walking speed by 0.11m/s (0.06 0.17m/s)
- Increase walking endurance by 37m (11-63m)


In the long term regardless of walking status, BWSTT

- Does not improve walking speed
- Does not improve walking endurance



Sub group analysis

(ONLY DONE FOR INDEPENDENT WALKING)











Intensity of treatment

• 3 months


- 5 times per week
- 3-4 times a week
- 3 times or less











- More than 4 weeks
- 4 weeks
- · Less than 4 weeks











Personalize this information to Mr Lee..

Mr. Lee, a 60 years old man who suffered a stroke 6 months ago requested you to refer home for body weight supported treadmill training (BWSTT).

He has right hemiplegia, and is currently walking independently without walking aids. He is unhappy with his current walking ability and want to know if BWSTT therapy could make him walk faster and for further distance.

His insurance odes not cover such therapy but he is willing to pay. He is currently undergoing conventional gait training.







Personalize this information to Mr Lee..

If you receive this treatment, you will:

- Walk faster by 0.11m/s (0.06 0.17m/s)
- Walk further by **37m (11-63m)**

At the end of the treatment session





Evidence Based Medicine

"Evidence-based medicine is the integration of best research evidence with clinical expertise and patient values"

David Sackett



Best Available Evidence

- Absolute benefits and harms
- Time horizon to benefit

Clinician's Judgment


- Individualized risk profile
- Prognosis^a
- Socio-personal context^b

Patient's Values

EBM

 Shared decision making














DIFFERENT TREATMENT DECISION







Email: julia@ummc.edu.my